Symptom-Onset Treatment for Women with Premenstrual Dysphoric Disorder
Authors:
- Kimberly A. YonkersKYKimberly A. Yonkers
- Gretchen A. HolthausenGHGretchen A. Holthausen
- Karalee PoschmanKPKaralee Poschman
- Heather B. HowellHHHeather B. Howell
- 1 April 2006
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 26 (2) , 198-202
Abstract
Symptoms of premenstrual dysphoric disorder (PMDD) respond to serotonin reuptake inhibitors when treatment is limited to 14 days of the menstrual cycle. Many women have less than a week of symptoms, and shorter treatment intervals would further reduce medication exposure and costs. Twenty women with PMDD were randomly assigned to either paroxetine CR or placebo for 1 cycle and crossed over to the other condition for a second cycle. Subjects initiated treatment when premenstrual symptoms began and stopped within 3 days of beginning menses. Women took capsules for an average of 9 days (range, 3-15 days), including the first few days of menses. Moderate "PMDD level" symptoms occurred in 1 subject (6%) for 2 days and 4 subjects (24%) for 1 day before starting paroxetine or placebo. Daily Record of Severity of Problems scores were lower in the paroxetine group compared with the placebo group, although the differences were not statistically significant. However, the mean on-treatment Inventory of Depressive Symptomatology (clinician-rated) score for the paroxetine group was 17.9 +/- 8.3 compared with 31.5 +/- 11.2 in the placebo group (adjusted mean difference = 13.6, P = 0.009). Response (Clinical Global Impressions Scale score of 1 or 2) occurred in 70% of subjects randomized to paroxetine CR and 10% of those assigned to placebo (chi2(1) = 7.5, P = 0.006). Discontinuation symptoms did not differ in the groups. These data suggest the need to further evaluate symptom-onset treatment in a larger randomized clinical trial.Keywords
This publication has 16 references indexed in Scilit:
- A Preliminary Study of Luteal Phase Versus Symptom-Onset Dosing With Escitalopram for Premenstrual Dysphoric DisorderThe Journal of Clinical Psychiatry, 2005
- Pretreatment pattern of symptom expression in premenstrual dysphoric disorderJournal of Affective Disorders, 2005
- Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trialClinical Therapeutics, 2002
- Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic reviewThe Lancet, 2000
- Luteal Phase Sertraline Treatment for Premenstrual Dysphoric Disorder: Results of a Double-blind, Placebo-Controlled, Crossover StudyArchives of Family Medicine, 1999
- Citalopram in Premenstrual DysphoriaJournal of Clinical Psychopharmacology, 1998
- Treatment of Premenstrual Dysphoric Disorder With Sertraline During the Luteal PhaseThe Journal of Clinical Psychiatry, 1998
- Intermittent Luteal Phase Sertraline Treatment of Dysphoric Premenstrual SyndromeThe Journal of Clinical Psychiatry, 1997
- Clomipramine Administered during the Luteal Phase Reduces the Symptoms of Premenstrual Syndrome: A Placebo-Controlled TrialNeuropsychopharmacology, 1993
- Premenstrual tension syndrome: The development of research diagnostic criteria and new rating scalesActa Psychiatrica Scandinavica, 1980